Physician profile
Ryan V Cantwell
NPI 1023007457
$8,741.74
in general payments reported to CMS, 2019-2025
48 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $1,061 · 2021: $849 · 2022: $829 · 2023: $1,226 · 2024: $1,790 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,147.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,108.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $973.69 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $839.09 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $558.37 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $501.47 | 2019-2025 | |
| Astellas Pharma US INC | $427.97 | 2019-2025 | Veozah |
| Lilly USA, LLC | $424.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $371.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $364.30 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $251.90 | 2019-2025 | |
| Exact Sciences Corporation | $248.87 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $211.37 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.58 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $187.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.24 | 2019-2025 | Jardiance |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $159.47 | 2021-2025 | |
| Abbott Laboratories | $140.93 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $138.50 | 2022-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $130.21 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $127.47 | 2023-2025 | Gemtesa |
| Inspire Medical Systems, INC. | $122.08 | 2024-2025 | Inspire |
| Dexcom, INC. | $107.40 | 2022-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $97.80 | 2020-2025 | Nexletol |
| Allergan, INC. | $93.22 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $89.31 | 2019-2024 | Gardasil 9, Vaqta, Gardasil |
| Shield Therapeutics INC | $83.51 | 2022-2025 | Accrufer |
| Eisai INC. | $55.55 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $51.13 | 2020-2021 | |
| Sanofi Pasteur INC. | $44.65 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $44.19 | 2019-2020 | |
| Pulmonx Corporation | $40.98 | 2024-2025 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Antares Pharma, INC. | $37.55 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Gilead Sciences, INC. | $34.04 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $33.74 | 2024-2025 | Voquezna |
| Radius Health, INC. | $33.45 | 2020-2021 | |
| Abiomed | $26.49 | 2025 | |
| Calliditas Therapeutics US INC. | $22.10 | 2025 | Tarpeyo |
| Teva Pharmaceuticals USA, INC. | $21.94 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.77 | 2021 | |
| Celgene Corporation | $20.69 | 2019 | |
| Hikma Pharmaceuticals USA | $20.19 | 2019 | |
| Biogen, INC. | $19.93 | 2025 | Leqembi |
| Ibsa Pharma INC. | $18.77 | 2024 | Licart, Tirosint |
| Stryker Corporation | $16.51 | 2019 | |
| Becton, Dickinson and Company | $15.74 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.57 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.03 | 2021 | |
| Shire North American Group INC | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Cantwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.